• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    4/15/24 4:31:28 PM ET
    $APM
    $ATHE
    $BIVI
    $CDIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APM alert in real time by email

    Gainers

    • Dynatronics (NASDAQ:DYNT) stock increased by 70.1% to $0.63 during Monday's after-market session. The company's market cap stands at $3.0 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock rose 14.28% to $1.14. The company's market cap stands at $24.6 million.
    • Aptorum Gr (NASDAQ:APM) shares rose 12.61% to $8.84. The market value of their outstanding shares is at $45.8 million.
    • Cue Health (NASDAQ:HLTH) shares moved upwards by 8.76% to $0.16. The company's market cap stands at $25.9 million.
    • P3 Health Partners (NASDAQ:PIII) shares increased by 8.37% to $0.53. The company's market cap stands at $63.7 million.
    • BioVie (NASDAQ:BIVI) shares rose 7.87% to $0.53. The market value of their outstanding shares is at $29.1 million.

    Losers

    • Poseida Therapeutics (NASDAQ:PSTX) shares declined by 15.2% to $2.06 during Monday's after-market session. The market value of their outstanding shares is at $198.7 million.
    • Alterity Therapeutics (NASDAQ:ATHE) shares fell 6.94% to $2.28. The market value of their outstanding shares is at $19.9 million.
    • Jaguar Health (NASDAQ:JAGX) shares fell 6.74% to $0.11. The company's market cap stands at $30.6 million.
    • Yield10 Bioscience (NASDAQ:YTEN) stock decreased by 6.4% to $0.26. The company's market cap stands at $4.0 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares declined by 6.26% to $0.65. The market value of their outstanding shares is at $23.2 million.
    • Longeveron (NASDAQ:LGVN) stock declined by 5.81% to $2.76. The market value of their outstanding shares is at $8.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APM
    $ATHE
    $BIVI
    $CDIO

    CompanyDatePrice TargetRatingAnalyst
    P3 Health Partners Inc.
    $PIII
    8/28/2025$20.00Buy
    Lake Street
    Alterity Therapeutics Limited
    $ATHE
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    Alterity Therapeutics Limited
    $ATHE
    12/12/2024$8.00Buy
    Maxim Group
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Poseida Therapeutics Inc.
    $PSTX
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    P3 Health Partners Inc.
    $PIII
    4/1/2024Buy → Neutral
    BTIG Research
    Cue Health Inc.
    $HLTH
    3/14/2024Buy → Neutral
    BTIG Research
    Yield10 Bioscience Inc.
    $YTEN
    2/8/2024Buy → Hold
    Lake Street
    More analyst ratings

    $APM
    $ATHE
    $BIVI
    $CDIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $APM
    $ATHE
    $BIVI
    $CDIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

    MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans

    3/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    P3 Health Partners Announces Fourth Quarter and Full Year 2025 Results

    Providing 2026 Guidance, Indicating a $10 Million Adjusted EBITDA Midpoint Management to Host Conference Call and Webcast March 26, 2026 at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance. "2025 was a year of meaningful progress in repositioning the business. We strengthened our contract economics, improved provider alignment, and built a more disciplined operating foundation. With that work in place, we enter 2026 with a clear path to profitability and approxi

    3/26/26 4:05:00 PM ET
    $PIII
    Medical/Nursing Services
    Health Care

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ATHE
    $BIVI
    $CDIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Willard Stephen H was granted 400,000 shares and covered exercise/tax liability with 105,533 shares (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:59:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Willard Stephen H claimed no ownership of stock in the company (SEC Form 3)

    3 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:58:57 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Micek John was granted 7,377 shares, increasing direct ownership by 13,919% to 7,430 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    3/12/26 3:03:56 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ATHE
    $BIVI
    $CDIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on P3 Health Partners with a new price target

    Lake Street resumed coverage of P3 Health Partners with a rating of Buy and set a new price target of $20.00

    8/28/25 8:10:21 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Alterity Therapeutics with a new price target

    Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00

    12/12/24 8:39:51 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ATHE
    $BIVI
    $CDIO
    SEC Filings

    View All

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    3/30/26 6:03:09 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Aptorum Group Limited

    20-F - Aptorum Group Ltd (0001734005) (Filer)

    3/27/26 4:02:32 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 6-K/A filed by Aptorum Group Limited

    6-K/A - Aptorum Group Ltd (0001734005) (Filer)

    3/26/26 4:30:08 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ATHE
    $BIVI
    $CDIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ATHE
    $BIVI
    $CDIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by P3 Health Partners Inc.

    SC 13G - P3 Health Partners Inc. (0001832511) (Subject)

    11/14/24 4:33:46 PM ET
    $PIII
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APM
    $ATHE
    $BIVI
    $CDIO
    Financials

    Live finance-specific insights

    View All

    P3 Health Partners Announces Fourth Quarter and Full Year 2025 Results

    Providing 2026 Guidance, Indicating a $10 Million Adjusted EBITDA Midpoint Management to Host Conference Call and Webcast March 26, 2026 at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance. "2025 was a year of meaningful progress in repositioning the business. We strengthened our contract economics, improved provider alignment, and built a more disciplined operating foundation. With that work in place, we enter 2026 with a clear path to profitability and approxi

    3/26/26 4:05:00 PM ET
    $PIII
    Medical/Nursing Services
    Health Care

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for fourth quarter and full year 2025 on Thursday, March 26, 2026. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Fourth Quarter and Full Year 2025 Earnings Conference Call Date & Time March 26, 2026, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 International 1-412-317-0692 Ask to be joined into t

    3/13/26 8:05:00 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    $APM
    $ATHE
    $BIVI
    $CDIO
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care